QuitBot Program for Cancer Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new smartphone app, QuitBot, and a text messaging program designed to help American Indians and Alaska Natives quit smoking commercial tobacco. The goal is to determine which method more effectively supports individuals in setting and achieving their quitting goals. Participants will receive either interactive chatbot messages or supportive text messages over 42 days. This trial suits those who identify as American Indian or Alaska Native, have smoked daily for the past year, and are interested in quitting smoking with the help of a smartphone. As an unphased trial, this study provides a unique opportunity to explore innovative quitting methods tailored to the community.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It focuses on quitting smoking, so it's best to consult with the trial coordinators or your doctor for guidance.
What prior data suggests that the QuitBot program is safe for smoking cessation?
Research shows that the QuitBot program, which uses chatbots and text messages to help people stop smoking, has been well-received by users. In earlier studies, the QuitBot chatbot kept users engaged and helped people quit smoking. The program includes short chats that focus on setting goals to quit and staying motivated. Importantly, no major safety issues or negative effects have been reported, suggesting that the QuitBot app is generally safe for users. Additionally, expert systems like QuitBot have helped 22% to 26% of participants quit smoking, offering encouragement for those wanting to quit.12345
Why are researchers excited about this trial?
Researchers are excited about the QuitBot program because it offers a fresh take on smoking cessation through digital means. Unlike traditional methods like nicotine replacement therapy or counseling, QuitBot uses a chatbot and text messaging to support users over a 42-day period. This approach harnesses technology to provide personalized, real-time assistance, making it more accessible and engaging for users. By delivering support directly to participants’ phones, QuitBot aims to fit seamlessly into daily life, potentially improving adherence and success rates in quitting smoking.
What evidence suggests that this trial's programs could be effective for smoking cessation among AI/AN populations?
Research has shown that both the QuitBot chatbot and text messaging programs, studied in this trial, can help people quit smoking. Participants will be assigned to either the QuitBot chatbot or the text messaging program. In a small initial study, the QuitBot chatbot demonstrated high user engagement, with many participants quitting smoking and 96% remaining involved after three months. These results suggest this method works well. Another study found that text messaging helped more people quit smoking compared to usual treatments. Both programs aim to offer personalized support, which is crucial for helping people stay smoke-free.23678
Who Is on the Research Team?
Jonathan B Bricker
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Are You a Good Fit for This Trial?
This trial is for American Indians and Alaska Natives who are looking to quit smoking. It's designed to help them with personalized support through a smartphone app called QuitBot and text messaging programs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily QuitBot program messages about quitting smoking over 42 days
Follow-up
Participants are monitored for smoking cessation success and engagement with QuitBot
What Are the Treatments Tested in This Trial?
Interventions
- QuitBot Smoking Cessation Chatbot Program
- QuitBot Smoking Cessation Text Messaging Program
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fred Hutchinson Cancer Center
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator